Ottawa, ON / Business Wire / February 18, 2021 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce that a paper “Evaluation …Read More
Media
Recent News
-
18
Feb
2021Avivagen Announces the Publication of its New Zealand OxC-betaTM Livestock Dairy Trial for Use Against Sub-Clinical Mastitis
-
16
Feb
2021Avivagen Inc. Announces Closing Of $7.5 Million Bought Deal Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, ON / Business Wire/– February 16, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support …Read More
-
09
Feb
2021Avivagen Inc. Announces Filing Of Final Short Form Prospectus For Previously Announced $7.5 Million Bought Deal Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, ON / Business Wire/– February 9, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune …Read More
-
27
Jan
2021Avivagen Inc. Announces Upsize To Previously Announced Bought Deal Unit Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, ON / Business Wire/– January 27, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune …Read More
-
26
Jan
2021Avivagen Announces Six Tonne Order of OxC-betaTM Livestock from New Customer in Mexico
Significant and ongoing order complements previous ten tonne order from established customer Industrias Melder Significant and ongoing order complements previous ten tonne order from established customer Industrias Melder Ottawa, ON / Business Wire/ January 26, 2021 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, …Read More
Media Coverage
-
Avivagen CEO Interviewed on C-Suite At The Open
Kym Anthony, CEO of Avivagen, was recently interviewed by Karoline Hunter, Head of TSX Company Services at the TMX group.
The interview covered the company story and gives a look ahead at the future of Avivagen’s OxC-BetaTM.
The interview also covers Immune Priming, its powerful anti-inflammatory effect, and its efficacy in improving Gut Health.
-
Copyright © 2021 Avivagen. All Rights Reserved.
